Back to top

Image: Bigstock

Nasdaq (NDAQ) Q1 Earnings & Revenues Top Estimates, Grow Y/Y

Read MoreHide Full Article

Have you been eager to see how Nasdaq, Inc. (NDAQ - Free Report) , performed in Q1 in comparison with the market expectations? Let’s quickly scan through the key facts from this NY-based major exchange operator’s earnings release this morning:

An Earnings Beat

Nasdaq reported adjusted earnings per share of $1.24 per share, beating the Zacks Consensus Estimate of $1.18. Earnings improved 31% year over year.

Improved revenues, higher volumes, lower tax incidence and solid market share aided the upside.

Nasdaq, Inc. Price and EPS Surprise

How Was the Estimate Revision Trend?

You should note that the earnings estimate for Nasdaq depicted neutral stance prior to the earnings release. The Zacks Consensus Estimate remained unchanged at $1.18 per share over the last 7 days.

Nasdaq has a solid earnings surprise history. The company surpassed the Zacks Consensus Estimate by an average of 4.72% in the trailing four quarters.

Revenues Beat

Nasdaq’s revenues of $666 million in the quarter increased 15% year over year. The Zacks Consensus Estimate was $644 million.

Key Takeaways

Adjusted operating expenses were $353 million in the reported quarter, up 15% from the year-ago quarter.

The Nasdaq Stock Market welcomed 62 new listings, 37 of which were IPOs.

As of Mar 31, 2018, long term debt decreased 15.3% over 2017 end level to $3.2 billion.

The company returned $162 million to its shareholders through dividends and share buybacks.

The company expects its 2018 non-GAAP operating expense in the range of $1,295–$1,335 million.

What Zacks Rank Says

Nasdaq carries a Zacks Rank #3 (Hold). However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change. Now it all depends on what sense the just-released report makes to the analysts.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Check back later for our full write up on this Nasdaq earnings report!

Investor Alert: Breakthroughs Pending

A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.

Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.

Click here to see them >>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Nasdaq, Inc. (NDAQ) - free report >>

Published in